Entering text into the input field will update the search result below

Celgene's ozanimod successful in second late-stage MS study, regulatory submissions on tap by year-end

May 22, 2017 8:14 AM ETCelgene Corporation (CELG) StockBy: Douglas W. House, SA News Editor7 Comments
  • Celgene (NASDAQ:CELG) is up a fraction premarket on the heels of its announcement of positive results from a second Phase 3 clinical trial, RADIANCE, assessing ozanimod (formerly RPC1063) for the treatment of relapsing multiple sclerosis (RMS).
  • The study met the primary endpoint of reducing annualized relapse rate compared to Biogen's (BIIB) Avonex (interferon beta-1a).
  • The company reported successful results from its first Phase 3, SUNBEAM, in February.
  • Detailed results will be submitted for presentation at an upcoming medical conference. Global regulatory filings will commence by year-end.
  • Previously: Celgene's ozanimod successful in late-stage MS study; shares up a fraction premarket (Feb. 17)

Recommended For You

Related Stocks

SymbolLast Price% Chg
CELG--
Celgene Corporation